News & Updates

Topical diclofenac offers no benefit over oral ibuprofen for acute low back pain

06 Mar 2024

Topical diclofenac does not appear to significantly improve functional outcome in acute musculoskeletal low back pain as compared with oral ibuprofen, with no added benefit when co-administered with oral ibuprofen, according to a study.

Topical diclofenac offers no benefit over oral ibuprofen for acute low back pain

06 Mar 2024

Original New Drug Application Approvals by US FDA (16-29 February 2024)

06 Mar 2024

New drug applications approved by US FDA as of 16-29 February 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-29 February 2024)

06 Mar 2024

Cannabis use detrimental to heart health

05 Mar 2024 by

Cannabis users may be putting themselves at risk of adverse cardiovascular outcomes, with the risk increasing proportionately with the frequency of use.

Cannabis use detrimental to heart health

05 Mar 2024

Extraoral manifestation not uncommon in osteonecrosis of the jaw

05 Mar 2024

Medication-related osteonecrosis of the jaw (MRONJ), a major side effect of using bone-modifying agents (BMA) for cancer or osteoporosis, normally manifests intraorally. However, some patients may have an extraoral manifestation of erythematous swelling or fistulas localized to the jaw area, according to a recent study.

Extraoral manifestation not uncommon in osteonecrosis of the jaw

05 Mar 2024

Ramipril on par with sacubitril/valsartan in acute MI

05 Mar 2024

Combination treatment with sacubitril and valsartan appears to be no better than ramipril in reducing the risk of cardiovascular death and heart failure (HF) in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction, regardless of AMI type, reveals a study.

Ramipril on par with sacubitril/valsartan in acute MI

05 Mar 2024

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024 by

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024

Nirmatrelvir reduces the risk of long COVID

05 Mar 2024

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹

Nirmatrelvir reduces the risk of long COVID

05 Mar 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024 by

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024 by

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024

News & Updates

Filter by Specialty:

Specialty:

Topical diclofenac offers no benefit over oral ibuprofen for acute low back pain

Topical diclofenac offers no benefit over oral ibuprofen for acute low back pain

Original New Drug Application Approvals by US FDA (16-29 February 2024)

Original New Drug Application Approvals by US FDA (16-29 February 2024)

Cannabis use detrimental to heart health

Cannabis use detrimental to heart health

Extraoral manifestation not uncommon in osteonecrosis of the jaw

Extraoral manifestation not uncommon in osteonecrosis of the jaw

Ramipril on par with sacubitril/valsartan in acute MI

Ramipril on par with sacubitril/valsartan in acute MI

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

Nirmatrelvir reduces the risk of long COVID

Nirmatrelvir reduces the risk of long COVID

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

High-dose PPI use among cirrhotic patients poses risk of death, complications

High-dose PPI use among cirrhotic patients poses risk of death, complications

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus